Loading stock data…
ClearPoint Neuro (CLPT)
$14.12-0.37 (-2.55%)
Market ClosedLast close Jul 24
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ClearPoint Neuro, Inc. in the Healthcare sector is trading at $14.12 with a market capitalization of $400M. Wall Street consensus targets $28.33 (3 analysts), implying a +100.7% move over the next 12 months. The stock is currently 53% below its 52-week high of $30.10, remaining 3.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +100.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 17) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $12.13M↑ | $10.41M↑ | $8.86M↓ | $9.21M↑ | $8.48M |
| Gross Profit | $7.76M↑ | $6.40M↑ | $5.60M↑ | $5.56M↑ | $5.13M |
| Operating Income | -$8.48M↓ | -$7.04M↓ | -$5.28M↑ | -$5.68M↑ | -$6.16M |
| Net Income | -$9.55M↓ | -$7.79M↓ | -$5.89M↓ | -$5.84M↑ | -$6.03M |
Peer Comparison
JNJUNHPFE
Fundamentals
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint sy...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$399.76M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-154.27%
Volume
Today's trading volume
466,956
Recent News
DarioHealth (DRIO) Moves 12.9% Higher: Will This Strength Last?
DarioHealth (DRIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?
ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ClearPoint Neuro Shares Jump as FDA Progress for UniQure Therapy Highlights Platform Value
ClearPoint Neuro (NASDAQ:CLPT) surged 50% on Wednesday after partner company UniQure announced a significant regulatory milestone for its Huntington’s disease treatment candidate, AMT-130. Investors responded positively to the update, which could accelerate development of a therapy that relies on ClearPoint’s technology platform for delivery.
How The ClearPoint Neuro (CLPT) Narrative Is Shifting On Partnerships Valuation And FDA Risks
ClearPoint Neuro’s fair value estimate has been trimmed from US$25.00 to US$22.00, roughly a 12% reduction in the modeled price target. Analysts link this reset to a balance of optimism around more than 60 biopharma partnerships and expedited intracranial programs, as well as caution tied to recent FDA feedback and its impact on revenue assumptions. As you read on, you will see how this evolving narrative could influence how you track the stock and its key milestones over time. Analyst Price...
ClearPoint Neuro Inc (CLPT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth
ClearPoint Neuro Inc (CLPT) reports a 43% revenue increase and strategic advancements despite rising operational costs.